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EXTENDED REPORT
Anti-chromatin antibodies in systemic lupus
erythematosus: a useful marker for lupus nephropathy
R Cervera, O Viñas, M Ramos-Casals, J Font, M García-Carrasco, A Sisó, F Ramírez,
Y Machuca, J Vives, M Ingelmo, R W Burlingame
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ann Rheum Dis 2003;62:431–434
Background: Anti-chromatin antibodies have recently been described in patients with systemic lupus
erythematosus (SLE) and it has been suggested that their presence is associated with lupus nephritis.
Objective: To assess the prevalence and clinical associations of these antibodies in SLE.
Methods: The presence of anti-chromatin antibodies in 100 patients with SLE was investigated by an
enzyme linked immunosorbent assay (ELISA). To determine the specificity of these antibodies, 100
patients with primary Sjögren’s syndrome, 30 with primary antiphospholipid syndrome (APS), 10 with
systemic sclerosis, and 100 normal controls were also tested.
Results: Positive levels were detected in 69/100 (69%) patients with SLE. In contrast, they were found
in only 8/100 (8%) of those with primary Sjögren’s syndrome, in 1/10 (10%) with systemic sclerosis,
in 2/30 (7%) with primary APS, and in none of the 100 healthy controls. Patients with anti-chromatin
antibodies had a twofold higher prevalence of lupus nephropathy than those without these antibodies
(58% v 29%, p<0.01). A significant correlation was found between the levels of anti-chromatin anti-
bodies and disease activity score as measured by the European Consensus Lupus Activity Measurement
(ECLAM; p=0.011).
Conclusions: The measurement of anti-chromatin antibodies appears to be a useful addition to the
laboratory tests that can help in the diagnosis and treatment of SLE. These antibodies are both sensitive
and specific for SLE, and are a useful marker for an increased risk of lupus nephritis.
Systemic lupus erythematosus (SLE) is the prototypicautoimmune connective tissue disease. It may affect anyorgan of the body and display a broad spectrum of clini-
cal and immunological manifestations. However, it is now
thought that patients with SLE can be divided into more
homogeneous subsets of pathogenic, therapeutic, and prog-
nostic significance.1
The presence of certain autoantibodies is one of the factors
associated with some symptoms of the disease and aids in the
classification of patients with SLE into specific subsets. This is
the case for antiphospholipid antibodies, which are clearly
associated with the development of thrombotic events and
obstetric morbidity,2 anti-ribonuclear protein (RNP) antibod-
ies that are markers of myositis and Raynaud’s phenomenon,3
and anti-SSA/Ro that are associated with congenital heart
abnormalities in newborn infants.4 One of the most severe
events in the course of SLE is the development of
glomerulonephritis,5 and much effort has been spent to find a
useful and early marker of this complication. Anti-dsDNA
antibodies are often associated with lupus nephritis,6 and the
presence of anti-dsDNA is a hallmark of SLE.7 8
However, evidence has accumulated in recent years that
anti-chromatin autoantibodies are correlated even better with
lupus nephritis than anti-dsDNA.9–12 Chromatin is the native
histone-DNA complex found in the nucleus of eukaryotic
cells, and it is organised into a repeating series of nucleo-
somes. Anti-chromatin-chromatin immune complexes can
bind to the glomerular basement membrane in vivo.13
Chromatin (or nucleosomes) is an antigen for T and B cells
from patients with SLE.12 14 Additionally, anti-chromatin anti-
bodies are a ubiquitous feature of murine lupus,15 and are nec-
essary but not sufficient for the development of glomerulo-
nephritis in one strain of mouse.16 It was found that
anti-chromatin always preceded the appearance of anti-
dsDNA antibodies in two strains of mice, and the suggestion
was made that anti-dsDNA antibodies were a subset of
anti-chromatin antibodies.15
In this study we investigated the prevalence of both
anti-dsDNA and anti-chromatin antibodies in a large series of
patients with SLE in order to assess their clinical significance
and, particularly, their value as amarker of lupus nephropathy.
To determine the specificity of these antibodies for SLE, a large
number of patients with other connective tissue diseases were
tested for anti-chromatin antibodies. It was also possible to
follow the antibodies over time from serial bleeds of some
patients with SLE.
PATIENTS AND METHODS
Patients and controls
Clinical and laboratory features of 100 consecutive and unse-
lected patients (93 female, seven male; mean (SD) age 37 (14)
years, range 11–70 years) with SLEwere prospectively studied.
All fulfilled four or more of the 1982 American College of
Rheumatology (ACR) revised criteria for the classification of
SLE.8
The disease control groups consisted of 100 patients with
primary Sjögren’s syndrome (classified according to the Euro-
pean criteria),17 30 with primary antiphospholipid syndrome
(APS) (categorised according to the preliminary criteria for
the classification of APS),18 and 10 with systemic sclerosis
(classified according to the ACR preliminary criteria).19 The
normal control group consisted of 100 healthy blood donors
from the blood bank of our hospital.
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Definition of clinical features and disease activity
The patients had been attending our institute either as in- or
outpatients between 1999 and 2000. All had documented
medical histories and underwent a medical interview as well
as a routine general physical examination by a qualified
internist. A serum sample from each patient was collected for
the immunological tests. Clinical and serological characteris-
tics of all these patients were collected in a protocol form.
Salient features included in this protocol were: (a) gender, (b)
age, (c) laboratory features, and (d) clinical manifestations at
the time blood was drawn. Information collected in the proto-
col forms was transferred to a computerised database
program. The study was performed according to the principles
of the Declaration of Helsinki.
The clinical manifestations evaluated in this protocol were
defined according to the recommendations of the ACR
glossary committee.20 Specifically, nephropathy was consid-
ered when patients presented (a) persistent proteinuria >0.5
g/day or greater than 3+ if measurement was not performed;
or (b) cellular casts (may be red cell, haemoglobin, granular,
tubular, or mixed); or (c) otherwise unexplained rise in serum
creatinine >75 µmol/l. Renal biopsies were reviewed by two
pathologists and categorised according to the modified classi-
fication proposed by the World Health Organisation21: type
I—normal kidney; type II—mesangial glomerulonephritis
(presence of mesangial deposits with mesangial hypercellu-
larity); type III—focal proliferative glomerulonephritis (in-
flammatory changes affecting some glomeruli but leaving
other unaffected); type IV—diffuse proliferative glomerulo-
nephritis (virtually all glomeruli show inflammation); type
V—membranous nephropathy (diffuse generalised thickening
of the capillary wall and predominant intramembranous
and/or subepithelial electrodense deposits, without inflamma-
tory changes).
Disease activity was assessed by the European Consensus
Lupus Activity Measurement (ECLAM).22
Detection of autoantibodies
Anti-chromatin antibodies of the IgG isotype were measured
by a commercial semiquantitative enzyme linked immuno-
sorbent assay (ELISA; INOVA Diagnostics Inc, San Diego, CA)
according to the manufacturer’s instructions. Antinuclear
antibodies were determined by indirect immunofluorescence
using triple tissue cryostat sections (liver-stomach-kidney)
and Hep-2 cells as substrate (Euroimmun). Anti-dsDNA anti-
bodies were determined by Farr’s ammonium sulphate
precipitation technique (Amerlex, Trinity Biotech, Ireland).23
Antibodies to extractable nuclear antigens of the IgG isotype,
including Ro(SSA), La(SSB), U1-snRNP, and Sm were
detected by ELISA (Captia, Trinity Biotech, Ireland). Rheuma-
toid factor was detected by nephelometry (Behring). Anticar-
diolipin antibodies of the IgG and IgM isotypes were
measured by an ELISA, as previously described.23 The lupus
anticoagulant activity was detected by coagulation assays, fol-
lowing the guidelines of the International Society on Throm-
bosis and Haemostasis (Scientific Subcommittee on Lupus
Anticoagulants/Phospholipid Dependent Antibodies).24
Statistical analysis
Conventional χ2 and Fisher’s exact tests were used for analys-
ing qualitative differences, and Student’s t test was used for
comparison of means, assuming similar variance in independ-
ent samples. A value of p<0.05 was taken to indicate signifi-
cance. When several independent variables appeared to have
statistical significance in the univariate analysis, a logistic
regression test was performed for multivariate analysis to rule
out possible confounding variables. Only those variables
showing statistical significance in the multivariate analysis
were considered significant in this study. The odds ratio (OR)
was calculated for assessing the risk of appearance of each
variable. A lower limit of the 95% confidence interval (CI) that
exceeded 1.0 was taken to indicate statistical significance in
the case of positive association and an upper limit lower than
1.0 in the case of negative association. Results of the analysis
of continuous variables are indicated as mean (SD). Linear
regression analysis was performed for comparison of continu-
ous variables. This statistical analysis was performed by the
SPSS and STATCALC programs using the information stored
in the database program.
RESULTS
Prevalence of anti-chromatin antibodies
Positive levels of anti-chromatin antibodies (>20 U) were
detected in 69/100 (69%) patients with SLE. In contrast, they
were found in only 8/100 (8%) patients with primary Sjögren’s
syndrome, in 1/10 (10%) patients with systemic sclerosis, in
2/30 (7%) patients with primary APS, and in 0/100 (0%)
healthy blood donors (table 1).
Relationship between anti-chromatin antibodies and
clinical features
Fifty two (52%) patients with SLE had clinical evidence of
lupus nephropathy at the time of the protocol study. Renal
biopsies performed at the time of clinical diagnosis of renal
involvement had disclosed type IV lesions in 19 patients, type
III in 15, type II in 11, and type V in 7. Forty two of the patients
with nephropathy were positive for anti-chromatin antibod-
ies, yielding a sensitivity of these antibodies for lupus
nephropathy of 81% and a specificity of 39%. Patients with
anti-chromatin antibodies had a twofold higher prevalence of
lupus nephropathy than those without these antibodies (58%
v 29%, p<0.01; OR=3.4, 95% CI 1.3 to 9.3). The mean level of
anti-chromatin antibodies in patients with lupus nephropathy
was 68 U and in patients without nephropathy 42 U (p<0.01).
No differences in the prevalence of the other clinical mani-
festations were found among patients with and without anti-
chromatin antibodies (table 2).
Table 1 Prevalence of anti-chromatin antibodies in
systemic autoimmune diseases and controls
Group
Anti-chromatin
antibodies
No (%) p
Systemic lupus erythematosus (n=100) 69 (69) <0.05
Primary Sjögren’s syndrome (n=100) 8 (8) –
Systemic sclerosis (n=10) 1 (10) –
Primary antiphospholipid syndrome (n=30) 2 (7) –
Healthy blood donors (n=100) 0 (0) –
Table 2 Prevalence of active SLE clinical
manifestations in patients with and without
anti-chromatin antibodies. Results are shown as No (%)
Manifestations
Anti-chromatin antibodies
p
Positive
(n=69)
Negative
(n=31)
Cutaneous 30 (43) 14 (45) NS
Arthritis 22 (32) 10 (32) NS
Serositis 2 (3) 0 (0) NS
Haematological 4 (6) 2 (6) NS
Nephropathy 40 (58) 9 (29) <0.01
Central nervous system 1 (1) 0 (0) NS
Thrombosis 1 (1) 0 (0) NS
NS, not significant.
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A significant correlation was found between the levels of
anti-chromatin antibodies and disease activity score as
measured by ECLAM (p=0.011, R2=0.0689) (fig 1).
Relationship between anti-dsDNA antibodies and
clinical features
Positive levels of anti-dsDNA antibodies (>15 U) were found
in 55 (55%) patients with SLE but in none of the other groups
of patients. Thirty nine of the 52 patients with nephropathy
were positive for anti-dsDNA, yielding a sensitivity of these
antibodies for lupus nephropathy of 75% and a specificity of
63%. Patients with anti-dsDNA antibodies were also found to
have a higher prevalence of lupus nephropathy than those
without these antibodies (71% v 32%, p<0.001; OR=5.4; 95%
CI 2 to 14.8). No differences in the prevalence of the other
clinical manifestations were found among patients with and
without anti-dsDNA antibodies.
Relationship between anti-chromatin antibodies and
anti-dsDNA and other serum autoantibodies
Forty nine patients had positive levels of both anti-dsDNA and
anti-chromatin antibodies (30/ 49 (61%) had lupus nephropa-
thy), but 20 patients had anti-chromatin without anti-dsDNA
antibodies (8/20 (40%) had lupus nephropathy), while only
six had anti-dsDNA without anti-chromatin antibodies (3/6
(50%) had lupus nephropathy). Additionally, a significant cor-
relation was found between the levels of anti-chromatin anti-
bodies and those of anti-dsDNA antibodies (p<0.0001, R2
=0.189) (fig 2).
Serial determinations of both anti-chromatin and anti-
dsDNA antibodies in three patients who developed lupus
nephropathy during the study disclosed that anti-chromatin
antibodies appeared before anti-dsDNA antibodies in one of
them (fig 3).
No correlation was found between anti-chromatin antibod-
ies and the presence of antinuclear antibodies, antiphospho-
lipid antibodies, antibodies to extractable nuclear antigens, or
rheumatoid factor.
DISCUSSION
Lupus nephropathy is a common complication of SLE that can
greatly influence the prognosis. Clearly, the mortality rate is
higher for patients with SLE with nephritis than in those
without renal disease,5 22 25 and some 10–60% of patients with
SLEwith nephritis (depending on genetic, socioeconomic, and
treatment differences) eventually develop end stage renal fail-
ure that requires dialysis or transplantation.26 Therefore,much
effort has been spent in finding a useful and early marker of
this complication. In this study we found that anti-chromatin
antibodies were clearly associated with the presence of lupus
nephritis with a sensitivity of 81%, which was slightly higher
than the 75% sensitivity of anti-dsDNA antibodies. Addition-
ally, a significant correlation was found between the levels of
anti-chromatin antibodies and disease activity.
Most studies have found that anti-chromatin/nucleosome
antibodies are quite sensitive and specific for SLE,9–12 27 but a
few have found a high prevalence in other diseases.11 28 29 In the
current study anti-chromatin showed a sensitivity of 69% in
the patients with SLE. There was a specificity of 100% in the
normal group, and 92% in the disease control group. These
results agree with the group of studies showing both high
sensitivity and specificity. Also in agreement with these stud-
ies, anti-chromatin showed a higher prevalence than anti-
dsDNA in patients with SLE. There are three reasons that
some studies showed high anti-chromatin reactivity in
patients with systemic sclerosis. In one case whole nucleo-
somes were used that contained small amounts of the Scl-70
antigen. The patients with systemic sclerosis who were
anti-Scl-70 positive were low positive on this preparation.29. In
another case, the antigen was denatured H2A plus denatured
H2B added to DNA (personal communication).28 In this case
the sera from patients with systemic sclerosis were reacting
with epitopes on the denatured histones that did not reconsti-
tute into their native conformations. In a third study11 a cut off
between positive and negative for anti-chromatin was chosen
Figure 1 Correlation between the levels of anti-chromatin
antibodies and SLE disease activity score as measured by ECLAM.
Figure 2 Correlation between the levels of anti-chromatin
antibodies and those of anti-dsDNA antibodies.
Figure 3 Serial determinations of both anti-chromatin and
anti-dsDNA antibodies in a patient who developed lupus
nephropathy during the study period, showing that anti-chromatin
antibodies appeared before anti-dsDNA antibodies.
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that was two standard deviations above the average of a non-
disease group. Because a non-disease group does not display a
Gaussian distribution of binding, this was not the appropriate
statistical method to choose a cut off (it was too low). When
H1-stripped chromatin or nucleosome core particles are used
as the antigen, and an appropriate cut off between positive
and negative is used, virtually no patients with systemic scle-
rosis are positive for anti-chromatin antibodies.27 29
In two studies using ELISA to measure anti-dsDNA and
anti-chromatin antibodies in both human and murine lupus,
no samples were positive for anti-dsDNA and negative for
anti-chromatin antibodies,9 15 suggesting that anti-dsDNA
were a subset of anti-chromatin. In this study, using the Farr
assay to measure anti-dsDNA antibodies, six samples were
anti-dsDNA positive but anti-chromatin antibody negative.
The most likely explanation is that some antibodies recognise
structures of DNA that can occur in protein-free DNA in solu-
tion but do not occur in the DNAwrapped around the histones
in chromatin that is bound to the solid phase of the ELISA
plate. None the less, in this study at least one patient did
develop anti-chromatin antibodies before developing anti-
dsDNA. Additionally, 49 of the 55 anti-dsDNA positive
samples were also anti-chromatin positive. Both these
findings are consistent with the concept that most of the anti-
dsDNA antibodies in patients with SLE are a subset of
anti-chromatin antibodies.
The measurement of anti-chromatin antibodies appears to
be a useful addition to the laboratory tests that can help in the
diagnosis and treatment of SLE. These antibodies are both
sensitive and specific for SLE, and are a useful marker for an
increased risk of lupus nephritis. Because a positive LE cell test
was often correlated withmore severe symptoms in lupus, and
anti-chromatin (previously called antideoxyribonucleoprotein)
antibodies are the main antibody causing LE cell
formation29—together with anti-histone H1 antibodies30—it is
not surprising to find correlations between disease and
anti-chromatin. Additionally, the finding that immune com-
plexes comprising chromatin and anti-chromatin can deposit
in the glomerular basement membrane of the kidney,13 and
that anti-chromatin antibodies are a necessary component for
the development of glomerulonephritis in one strain of
mouse,16 provides theoretical evidence that anti-chromatin
antibodies can have pathological properties in some patients
with SLE.
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